Chemical compounds

PTC Therapeutics Reports Second Quarter 2020 Financial Results and Provides a Corporate Update

Wednesday, August 5, 2020 - 9:01pm

SOUTH PLAINFIELD, N.J., Aug. 5, 2020 /PRNewswire/ --PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced a corporate update and reported financial results for the second quarter ending June 30, 2020.

Key Points: 
  • SOUTH PLAINFIELD, N.J., Aug. 5, 2020 /PRNewswire/ --PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced a corporate update and reported financial results for the second quarter ending June 30, 2020.
  • Key Second Quarter and Other Corporate Updates:
    Our Duchenne muscular dystrophy franchise had strong performance in the second quarter.
  • Translarna net product revenues were $38.6 million for the second quarter of 2020, compared to $57.8 million for the second quarter of 2019.
  • Emflaza net product revenues were $36.2 million for the second quarter of 2020, compared to $27.6 million for the second quarter of 2019.

ORIC Pharmaceuticals Expands Precision Oncology Pipeline with Exclusive Worldwide License to Highly Selective Allosteric PRC2 Inhibitors from Mirati Therapeutics

Wednesday, August 5, 2020 - 9:05pm

With ORICs focus on novel treatments for prostate cancer, ORIC is an ideal partner to further the research and development of this program.

Key Points: 
  • With ORICs focus on novel treatments for prostate cancer, ORIC is an ideal partner to further the research and development of this program.
  • Prior to entering into the license agreement with Mirati, ORIC generated compelling in vivo efficacy data in enzalutamide-resistant prostate cancer models with ORIC-944.
  • More recent scientific advances have focused on developing allosteric inhibitors of PRC2, which may help to address several limitations of first-generation PRC2 inhibitors.
  • Research conducted at ORIC demonstrated that allosteric inhibitors of PRC2 are more efficacious in treatment-resistant prostate cancer models than has been reported by traditional non-allosteric PRC2 inhibitors.

AVEO Oncology Announces $2.8M Development Milestone Earned from Kyowa Kirin

Wednesday, August 5, 2020 - 9:05pm

AVEO Oncology (Nasdaq: AVEO) today announced that it has earned a $2.8 million development milestone payment from partner Kyowa Kirin Co., Ltd. (Kyowa Kirin).

Key Points: 
  • AVEO Oncology (Nasdaq: AVEO) today announced that it has earned a $2.8 million development milestone payment from partner Kyowa Kirin Co., Ltd. (Kyowa Kirin).
  • This milestone marks an important step forward for AVEOs non-oncology pipeline, said Michael Bailey, president and chief executive officer of AVEO.
  • We believe tivozanibs potential in non-oncology indications is significant, and we look forward to seeing Kyowa Kirin move this formulation into the clinic.
  • Under the terms of AVEOs agreement with Kyowa Kirin, in addition to the previously-paid upfront payment of $25 million to AVEO and waiver of AVEOs obligation to make an $18 million milestone payment upon AVEO gaining U.S. marketing approval of tivozanib for renal cell carcinoma, and now the IND development milestone, Kyowa Kirin has also agreed to pay AVEO up to an additional $388 million in potential milestone payments upon the successful achievement of certain development, regulatory, and commercial objectives in non-oncology indications of tivozanib.

ACADIA Pharmaceuticals Reports Second Quarter 2020 Financial Results

Wednesday, August 5, 2020 - 9:05pm

ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders, today announced its financial results for the second quarter ended June 30, 2020.

Key Points: 
  • ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders, today announced its financial results for the second quarter ended June 30, 2020.
  • ACADIA announced top-line results from the Phase 3 CLARITY study of pimavanserin for adjunctive treatment in patients with major depressive disorder.
  • For the six months ended June 30, 2020 and 2019, ACADIA reported net product sales of $200.2 million and $146.2 million, respectively.
  • ACADIA management will review its second quarter financial results and operations via conference call and webcast today at 4:30 p.m. Eastern Time.

Charm Sciences Awarded 5 Year Contract for Vomitoxin Tests by USDA-FGIS

Wednesday, August 5, 2020 - 2:00pm

USDA-FGIS operates and oversees official grain inspection services throughout the United States and will use the DONQ2 test for official vomitoxin (DON) testing.

Key Points: 
  • USDA-FGIS operates and oversees official grain inspection services throughout the United States and will use the DONQ2 test for official vomitoxin (DON) testing.
  • USDA-FGIS used Charm to test for vomitoxin over the last five years as well, first with Charm's ROSA FAST5 DON test, and then with the DONQ2 test.
  • "Charm is excited to be awarded the DON contract for another five years to test grains in the FGIS's testing program," said Mark Tess, Ph.D., Mycotoxin Product Manager at Charm Sciences.
  • Like all of Charm's ROSA mycotoxin tests, the DONQ2 test can be read and recorded using the all-in-one Charm EZ-M system.

LORBRENA® (lorlatinib) Significantly Improves Progression-Free Survival in First-Line ALK-Positive Lung Cancer

Wednesday, August 5, 2020 - 1:00pm

IMPORTANT LORBRENA (lorlatinib) SAFETY INFORMATION FROM THE U.S. PRESCRIBING INFORMATION

Key Points: 
  • IMPORTANT LORBRENA (lorlatinib) SAFETY INFORMATION FROM THE U.S. PRESCRIBING INFORMATION
    Contraindications: LORBRENA is contraindicated in patients taking strong CYP3A inducers, due to the potential for serious hepatotoxicity.
  • Depending upon the relative importance of each drug, discontinue LORBRENA or the CYP3A inducer for persistent Grade 2 or higher hepatotoxicity.
  • Overall, 1.5% and 9% of patients required permanent or temporary discontinuation of LORBRENA, respectively, for a CNS effect; 8% required dose reduction.
  • Monitor serum cholesterol and triglycerides before initiating LORBRENA, 1 and 2 months after initiating LORBRENA, and periodically thereafter.

Curis Reports Second Quarter 2020 Financial Results

Tuesday, August 4, 2020 - 9:01pm

LEXINGTON, Mass., Aug. 4, 2020 /PRNewswire/ --Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today reported its financial results for the second quarter ended June 30, 2020.

Key Points: 
  • LEXINGTON, Mass., Aug. 4, 2020 /PRNewswire/ --Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today reported its financial results for the second quarter ended June 30, 2020.
  • Today, Curis announced that it will initiate a Phase 1 study evaluating CA-4948 in combination with ibrutinib, a BTK inhibitor, in the second half of 2020.
  • Curis expects to initiate a Phase 1a/1b study of CI-8993 in patients with relapsed / refractory solid tumors in the second half of 2020.
  • Revenues for the second quarter of 2020 were $2.4 million, as compared to $2.1 million for the same period in 2019.

Premier Inc. ProvideGx® Program Partners with Somerset Pharma to Stabilize Pricing, Enhance Competition for Sulfamethoxazole/Trimethoprim

Tuesday, August 4, 2020 - 1:00pm

(NASDAQ: PINC), through its ProvideGx program, has partnered with Somerset Pharma, LLC., to supply sulfamethoxazole/trimethoprim, an antibiotic combination used to treat respiratory infections, a common complication associated with COVID-19.

Key Points: 
  • (NASDAQ: PINC), through its ProvideGx program, has partnered with Somerset Pharma, LLC., to supply sulfamethoxazole/trimethoprim, an antibiotic combination used to treat respiratory infections, a common complication associated with COVID-19.
  • Somerset is a new market entrant for this drug, working to creating a viable, competitive alternative and second source of supply.
  • At the same time, this deal provides a long-term contract to Somerset, creating predictable demand for years into the future.
  • Together with privately owned, U.S.-based Somerset Therapeutics, established in 2015, Somerset develops, manufactures and markets generic injectable and ophthalmic drugs.

KemPharm to Report Second Quarter 2020 Financial Results

Tuesday, August 4, 2020 - 12:30pm

ET, to discuss its corporate and financial results for the second quarter 2020.

Key Points: 
  • ET, to discuss its corporate and financial results for the second quarter 2020.
  • An archive of the webcast and presentation will be available for 90 days beginning at approximately5:30 p.m.
  • In addition, KemPharm has received FDA approval for APADAZ, an immediate-release combination product containing benzhydrocodone, a prodrug of hydrocodone, and acetaminophen.
  • For more information on KemPharm and its pipeline of prodrug product candidates visit www.kempharm.com or connect with us on Twitter , LinkedIn , Facebook and YouTube .

Antibe Therapeutics Provides Corporate Update

Tuesday, August 4, 2020 - 12:00pm

(For further information, please see our website and updated Corporate Presentation).

Key Points: 
  • (For further information, please see our website and updated Corporate Presentation).
  • Blood pressure increases are viewed by medical practitioners globally as being an important proxy for the cardiovascular risk of NSAIDs.
  • We will be using otenaproxesul going forward, and our Corporate Presentation and website have been amended as such.
  • To this end, Antibe recently signed a contract with a leading academic institution in the US known for the quality of its hydrogen sulfide science.